Kimimichi Obata

Nessuna posizione attualmente

74 anni

Health Technology

Profilo

Kimimichi Obata worked as a Director at Precision System Science Co., Ltd.
from 2011 to 2014.
He was also the President & Representative Director at Precision System Science USA, Inc. from 2001 to 2014.
Additionally, he served as a Director at Universal Bio Research Co., Ltd.
from 2002 to 2014.

Precedenti posizioni note di Kimimichi Obata

Società	Posizione	Fine
PRECISION SYSTEM SCIENCE CO., LTD.	Direttore/Membro del Consiglio	16/11/2014
Universal Bio Research Co., Ltd.	Direttore/Membro del Consiglio	16/11/2014
Precision System Science USA, Inc. Precision System Science USA, Inc. Medical SpecialtiesHealth Technology Part of Precision System Science Co., Ltd., Precision System Science USA, Inc. is a company that provides user-friendly technology for DNA extraction. The company is based in Pleasanton, CA. The company offers MagDEA® Dx LV Prefilled reagents cartridges for consistent and uniform magnetic bead-based nucleic acid extractions for large, 1 to 5 mL, sample volumes. Akihiro Furukawa has been the CEO of the company since 2017.	Presidente	16/11/2014

Vedi nel dettaglio l'esperienza di Kimimichi Obata

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kimimichi Obata

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
PRECISION SYSTEM SCIENCE CO., LTD.	Health Technology

Aziende private	2
Universal Bio Research Co., Ltd.
Precision System Science USA, Inc. Precision System Science USA, Inc. Medical SpecialtiesHealth Technology Part of Precision System Science Co., Ltd., Precision System Science USA, Inc. is a company that provides user-friendly technology for DNA extraction. The company is based in Pleasanton, CA. The company offers MagDEA® Dx LV Prefilled reagents cartridges for consistent and uniform magnetic bead-based nucleic acid extractions for large, 1 to 5 mL, sample volumes. Akihiro Furukawa has been the CEO of the company since 2017.	Health Technology